DUBLIN, Nov. 26, 2013 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/h45rfk/the_medicines) has announced the addition of the "The Medicines Company's Cangrelor - Is it better than Plavix for Acute Coronary Syndrome?" report to their offering.
Cangrelor is a reversible, intravenous inhibitor of the P2Y12 receptor whose effect is to inhibit adenosine diphosphate-induced platelet aggregation. The Medicines Company is developing it for use in the setting of patients undergoing percutaneous coronary intervention procedures (PCI), specifically those who have not used Plavix or other P2Y12 inhibitors in the prior week. Two previous phase III trials failed to meet their primary endpoints. Thus, approval hangs on the results of a third trial, CHAMPION-PHOENIX that should report before year-end. This report explores the probability of a favorable phase III outcome, eventual approval, and the market opportunity.
Key Topics Covered:
1. Acute coronary syndromes (ACS)
2. Thrombosis is at the center of causality
3. Clinicians use several approaches to platelet inhibition
1. Phase I/II trials
2. Pivotal trials
CLINICAL AND REGULATORY DISCUSSION
1. Why did CHAMPION-PCI and CHAMPION-PLATFORM fail?
2. Given the PCI and PLATFORM results, what are the lessons for PHOENIX?
3. Are there meaningful safety concerns associated with cangrelor?
4. Are there any bleeding concerns?
5. Possible adverse pulmonary effects of cangrelor
6. What are the regulatory issues that cangrelor will face?
7. Other relevant FDA guidance
8. In summary
1. Overview of issues
2. Market estimates
3. Pipeline products
For more information visit http://www.researchandmarkets.com/research/h45rfk/the_medicines
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood , +353-1-481-1716, firstname.lastname@example.org
|SOURCE Research and Markets|
Copyright©2012 PR Newswire.
All rights reserved